Cost-Containment

Aetna, meanwhile, is talk about its efforts to adopt a low-friction prior authorization strategy.

A cancer center CEO at a Senate field hearing talked about her own organization's coverage.

The framework links U.S. drug prices to international benchmarks through manufacturer agreements and federal pricing mechanisms, with major implications for high-cost drugs like GLP-1s.

For employers' health plans, the new ATTR-CM specialty drugs could cost $500,000 per participant treated.

A stop-loss market veteran looks at the differences between the two types of ERISA self-funded plans.

The move might, or might not, affect employers that fail to offer enough affordable major medical coverage.